
Surmodics (SRDX) Stock Forecast & Price Target
Surmodics (SRDX) Analyst Ratings
Bulls say
Surmodics Inc. is poised for substantial revenue growth due to its strategic investment in a whole-products solutions approach, which has led to the establishment of a direct sales force for its Pounce thrombectomy and Sublime radial access products. Despite increased operating expenses associated with these initiatives, the company's focus on enhancing its Medical Device segment, which includes advanced performance coating technologies and innovative medical devices, demonstrates its commitment to strengthening its market position. Overall, this proactive investment strategy, particularly within the domestic market, positions Surmodics favorably for future financial performance.
Bears say
Surmodics Inc. is facing significant challenges, primarily due to declining sales of its SurVeil drug-coated balloon, which has been compounded by reduced license fee revenue and lower sales to its distribution partner, Abbott. The company anticipates a larger-than-expected decrease in SurVeil sales for fiscal year 2025, which raises concerns about overall revenue growth. Additionally, the impact of these headwinds, including diminished coating royalty and license fee catch-up payments, is likely to further strain the financial performance of its Medical Device segment, which is crucial for the company’s revenue generation.
This aggregate rating is based on analysts' research of Surmodics and is not a guaranteed prediction by Public.com or investment advice.
Surmodics (SRDX) Analyst Forecast & Price Prediction
Start investing in Surmodics (SRDX)
Order type
Buy in
Order amount
Est. shares
0 shares